MDGL MADRIGAL PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1157601 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $81.48M 28 sales by 9 insiders
- Filings on record
- 169 since 2021-08-04, latest 2026-09-11 16:57
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| FRIEDMAN PAUL A | Dir | — | $26.66M |
| Taub Rebecca | Dir | — | $21.68M |
| Sibold William John | Pres, CEO, Dir | — | $10.48M |
| BATE KENNETH | Dir | — | $8.03M |
| Levy Richard S | Dir | — | $7.36M |
| Dier Mardi | EVP, CFO | — | $3.77M |
| Huntsman Carole | Chief Commercial Off | — | $1.71M |
| Soergel David | Chief Medical Off | — | $952.0K |
| Kelley Shannon T | GC | — | $841.6K |
| Thakkar Rita | CAO | — | — |
Transactions 205
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-03-04 | 2025-02-28 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $341.07 | -1,227 | 3,728 | -25% | -$418.5K |
| D | 2025-02-28 | 2025-02-27 | MDGL | Sibold William John | Pres, CEO, Dir | M - OptEx | — | +50.0K | 104.3K | +92% | — |
| DM | 2025-02-28 | 2025-02-27 | MDGL | Daly James M | Dir | S - Sale+OE | $347.45 | -15.5K | 17.0K | -48% | -$5.38M |
| DM | 2025-02-28 | 2025-02-27 | MDGL | Daly James M | Dir | M - OptEx | $82.90 | +15.5K | 11.4K | New | +$1.28M |
| DM | 2025-02-28 | 2025-02-27 | MDGL | BATE KENNETH | Dir | S - Sale+OE | $356.44 | -20.0K | 21.8K | -48% | -$7.13M |
| DM | 2025-02-28 | 2025-02-27 | MDGL | BATE KENNETH | Dir | M - OptEx | $66.26 | +20.0K | 7,912 | New | +$1.33M |
| 2025-01-27 | 2025-01-24 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $335.24 | -1,584 | 54.3K | -3% | -$531.0K | |
| 2025-01-27 | 2025-01-24 | MDGL | Huntsman Carole | Chief Commercial Off | S - Sale | $335.24 | -347 | 10.4K | -3% | -$116.3K | |
| 2025-01-27 | 2025-01-24 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $335.24 | -103 | 4,955 | -2% | -$34.5K | |
| 2025-01-27 | 2025-01-24 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | S - Sale | $335.24 | -648 | 456.7K | -0.1% | -$217.2K | |
| 2025-01-17 | 2025-01-17 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $273.41 | -442 | 5,058 | -8% | -$120.8K | |
| 2025-01-17 | 2025-01-17 | MDGL | Kelley Shannon T | GC | S - Sale | $273.41 | -277 | 7,705 | -3% | -$75.7K | |
| 2025-01-17 | 2025-01-17 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | S - Sale | $273.41 | -1,689 | 457.3K | -0.4% | -$461.8K | |
| MI | 2024-12-05 | 2024-12-03 | MDGL | CRAVES FRED B | Dir | S - Sale | $315.31 | -3,600 | 11.5K | -24% | -$1.14M |
| MI | 2024-11-27 | 2024-11-25 | MDGL | CRAVES FRED B | Dir | S - Sale | $350.30 | -3,400 | 15.8K | -18% | -$1.19M |
| 2024-11-22 | 2024-11-21 | MDGL | Huntsman Carole | Chief Commercial Off | S - Sale | $316.92 | -688 | 10.8K | -6% | -$218.0K | |
| DT | 2024-11-08 | 2024-11-07 | MDGL | Levy Richard S | Dir | M - OptEx | $7.36 | +5,000 | 16.0K | +45% | +$36.8K |
| DT | 2024-11-08 | 2024-11-07 | MDGL | Levy Richard S | Dir | S - Sale+OE | $350.00 | -5,000 | 11.0K | -31% | -$1.75M |
| DMT | 2024-11-05 | 2024-11-01 | MDGL | Levy Richard S | Dir | S - Sale+OE | $300.94 | -5,000 | 11.0K | -31% | -$1.50M |
| DT | 2024-11-05 | 2024-11-01 | MDGL | Levy Richard S | Dir | M - OptEx | $7.36 | +5,000 | 16.0K | +45% | +$36.8K |
| 2024-09-17 | 2024-09-13 | MDGL | CRAVES FRED B | Dir | G - Gift | $0.00 | -15.0K | 360.1K | -4% | $0 | |
| 2024-09-11 | 2024-09-09 | MDGL | Sibold William John | Pres, CEO, Dir | S - Sale | $243.83 | -6,363 | 55.9K | -10% | -$1.55M | |
| D | 2024-08-19 | 2024-08-15 | MDGL | Kelley Shannon T | GC | A - Grant | $0.00 | +5,215 | 7,982 | +188% | $0 |
| DMI | 2024-06-27 | 2024-06-25 | MDGL | Baker Bros. Advisors (GP) LLC | Dir | A - Grant | $0.00 | +2,856 | 1.79M | +0.2% | $0 |
| D | 2024-06-27 | 2024-06-25 | MDGL | BATE KENNETH | Dir | A - Grant | $0.00 | +714 | 1,912 | +60% | $0 |
| D | 2024-06-27 | 2024-06-25 | MDGL | CRAVES FRED B | Dir | A - Grant | $0.00 | +714 | 375.1K | +0.2% | $0 |
| D | 2024-06-27 | 2024-06-25 | MDGL | FRIEDMAN PAUL A | Dir | A - Grant | $0.00 | +714 | 186.4K | +0.4% | $0 |
| D | 2024-06-27 | 2024-06-25 | MDGL | Daly James M | Dir | A - Grant | $0.00 | +714 | 1,912 | +60% | $0 |
| D | 2024-06-27 | 2024-06-25 | MDGL | Levy Richard S | Dir | A - Grant | $0.00 | +714 | 11.0K | +7% | $0 |
| D | 2024-06-18 | 2024-06-14 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $280.00 | -1,900 | 5,500 | -26% | -$532.0K |
| D | 2024-06-18 | 2024-06-14 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.09 | +1,900 | 7,400 | +35% | +$165.5K |
| D | 2024-06-14 | 2024-06-12 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $285.00 | -2,000 | 5,500 | -27% | -$570.0K |
| D | 2024-06-14 | 2024-06-12 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +2,000 | 7,500 | +36% | +$175.8K |
| 2024-06-13 | 2024-06-11 | MDGL | CRAVES FRED B | Dir | G - Gift | $0.00 | -39.0K | 374.4K | -9% | $0 | |
| I | 2024-06-13 | 2024-06-11 | MDGL | CRAVES FRED B | Dir | G - Gift | $0.00 | -45.9K | 11.2K | -80% | $0 |
| 2024-05-23 | 2024-05-21 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale | $231.34 | -1,036 | 5,500 | -16% | -$239.7K | |
| DMT | 2024-05-16 | 2024-05-14 | MDGL | CRAVES FRED B | Dir | M - OptEx | $103.02 | +22.5K | 435.9K | +5% | +$2.32M |
| DMT | 2024-05-16 | 2024-05-14 | MDGL | CRAVES FRED B | Dir | S - Sale+OE | $212.87 | -22.5K | 418.5K | -5% | -$4.79M |
| DMT | 2024-04-10 | 2024-04-08 | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $246.19 | -26.3K | 210.6K | -11% | -$6.47M |
| DT | 2024-04-10 | 2024-04-08 | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +26.3K | 212.0K | +14% | +$248.3K |
| DMT | 2024-04-10 | 2024-04-08 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | S - Sale+OE | $245.99 | -2,676 | 459.0K | -0.6% | -$658.3K |
| DT | 2024-04-10 | 2024-04-08 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | M - OptEx | $9.45 | +2,676 | 461.7K | +0.6% | +$25.3K |
| DM | 2024-04-05 | 2024-04-03+ | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | M - OptEx | $9.45 | +73.9K | 486.8K | +18% | +$698.2K |
| DM | 2024-04-05 | 2024-04-03+ | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | S - Sale+OE | $243.92 | -73.9K | 484.2K | -13% | -$18.02M |
| DM | 2024-04-05 | 2024-04-03+ | MDGL | FRIEDMAN PAUL A | Dir | S - Sale+OE | $243.93 | -73.7K | 188.2K | -28% | -$17.98M |
| DM | 2024-04-05 | 2024-04-03+ | MDGL | FRIEDMAN PAUL A | Dir | M - OptEx | $9.45 | +73.7K | 213.3K | +53% | +$696.7K |
| DM | 2024-04-03 | 2024-04-01+ | MDGL | BATE KENNETH | Dir | S - Sale+OE | $252.86 | -32.5K | 1,472 | -96% | -$8.22M |
| DM | 2024-04-03 | 2024-04-01+ | MDGL | BATE KENNETH | Dir | M - OptEx | $74.22 | +32.5K | 22.5K | New | +$2.41M |
| DMT | 2024-04-03 | 2024-04-01 | MDGL | Levy Richard S | Dir | M - OptEx | $63.92 | +11.0K | 21.3K | +107% | +$703.2K |
| DMT | 2024-04-03 | 2024-04-01 | MDGL | Levy Richard S | Dir | S - Sale+OE | $257.48 | -11.0K | 10.3K | -52% | -$2.83M |
| DM | 2024-04-03 | 2024-04-01+ | MDGL | Daly James M | Dir | M - OptEx | $102.23 | +32.5K | 22.8K | New | +$3.32M |
| DM | 2024-04-03 | 2024-04-01+ | MDGL | Daly James M | Dir | S - Sale+OE | $252.97 | -32.5K | 1,398 | -96% | -$8.22M |
| D | 2024-01-25 | 2024-01-23 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +12.2K | 62.2K | +24% | $0 |
| D | 2024-01-25 | 2024-01-23 | MDGL | Howarth Alex G. | CFO | A - Grant | $0.00 | +4,803 | 18.7K | +34% | $0 |
| D | 2024-01-25 | 2024-01-23 | MDGL | Lynch Brian Joseph | SVP, GC | A - Grant | $0.00 | +3,639 | 17.7K | +26% | $0 |
| D | 2024-01-25 | 2024-01-23 | MDGL | Huntsman Carole | Chief Commercial Off | A - Grant | $0.00 | +3,639 | 11.5K | +46% | $0 |
| D | 2024-01-25 | 2024-01-23 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | A - Grant | $0.00 | +5,786 | 20.8K | +39% | $0 |
| D | 2024-01-25 | 2024-01-23 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | A - Grant | $0.00 | +1,419 | 6,536 | +28% | $0 |
| 2024-01-18 | 2023-01-16 | MDGL | FRIEDMAN PAUL A | Dir | F - Tax | $243.92 | -2,254 | 20.0K | -10% | -$549.8K | |
| 2024-01-18 | 2024-01-16 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | F - Tax | $243.92 | -1,546 | 15.0K | -9% | -$377.1K | |
| 2024-01-18 | 2024-01-16 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | F - Tax | $243.92 | -550 | 5,117 | -10% | -$134.2K | |
| 2024-01-18 | 2024-01-16 | MDGL | Lynch Brian Joseph | SVP, GC | F - Tax | $243.92 | -949 | 14.1K | -6% | -$231.5K | |
| 2024-01-18 | 2024-01-16 | MDGL | Howarth Alex G. | CFO | F - Tax | $243.92 | -1,067 | 13.9K | -7% | -$260.3K | |
| DM | 2023-12-18 | 2023-12-14+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $235.50 | -4,000 | 6,667 | -37% | -$942.0K |
| DM | 2023-12-18 | 2023-12-14+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +4,000 | 7,667 | +109% | +$351.7K |
| DM | 2023-12-14 | 2023-12-12+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $222.82 | -3,800 | 5,667 | -40% | -$846.7K |
| DM | 2023-12-14 | 2023-12-12+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +3,800 | 8,167 | +87% | +$334.1K |
| MI | 2023-12-14 | 2023-12-13+ | MDGL | BAKER BROS. ADVISORS LP | Dir | P - Purchase | $221.20 | +101.8K | 1.72M | +6% | +$22.52M |
| MI | 2023-12-14 | 2023-12-12 | MDGL | 667, L.P. | Dir | P - Purchase | $218.31 | +34.6K | 1.67M | +2% | +$7.55M |
| MI | 2023-12-11 | 2023-12-07 | MDGL | CRAVES FRED B | Dir | J - Other | $0.00 | -1.56M | 0 | -100% | $0 |
| I | 2023-12-11 | 2023-01-30 | MDGL | CRAVES FRED B | Dir | G - Gift | $0.00 | -3,557 | 57.1K | -6% | $0 |
| DM | 2023-12-06 | 2023-12-04+ | MDGL | Lynch Brian Joseph | SVP, GC | M - OptEx | $83.28 | +2,800 | 16.0K | +21% | +$233.2K |
| DM | 2023-12-06 | 2023-12-04+ | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $221.89 | -2,800 | 15.0K | -16% | -$621.3K |
| DM | 2023-12-01 | 2023-11-29+ | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $201.50 | -7,000 | 15.0K | -32% | -$1.41M |
| DM | 2023-12-01 | 2023-11-29+ | MDGL | Lynch Brian Joseph | SVP, GC | M - OptEx | $73.75 | +7,000 | 19.0K | +58% | +$516.2K |
| D | 2023-11-22 | 2023-11-20 | MDGL | Huntsman Carole | Chief Commercial Off | A - Grant | $0.00 | +7,834 | 7,834 | New | $0 |
| MI | 2023-11-21 | 2023-11-21 | MDGL | BAKER JULIAN | Dir | P - Purchase | $188.47 | +64.3K | 1.61M | +4% | +$12.13M |
| MI | 2023-11-21 | 2023-11-17+ | MDGL | Baker Brothers Life Sciences LP | Dir | P - Purchase | $178.11 | +67.1K | 1.55M | +5% | +$11.95M |
| MI | 2023-11-15 | 2023-11-13+ | MDGL | BAKER FELIX | Dir | P - Purchase | $146.99 | +107.5K | 1.48M | +8% | +$15.80M |
| MI | 2023-11-15 | 2023-11-14+ | MDGL | BAKER JULIAN | Dir | P - Purchase | $158.13 | +49.4K | 1.55M | +3% | +$7.81M |
| D | 2023-09-13 | 2023-09-11 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
| MI | 2023-06-20 | 2023-06-15 | MDGL | Baker Brothers Life Sciences LP | Dir | A - Grant | $0.00 | +9,584 | 1.40M | +0.7% | $0 |
| 2023-06-20 | 2023-06-15 | MDGL | Levy Richard S | Dir | A - Grant | $0.00 | +1,198 | 10.3K | +13% | $0 | |
| 2023-06-20 | 2023-06-15 | MDGL | CRAVES FRED B | Dir | A - Grant | $0.00 | +1,198 | 362.6K | +0.3% | $0 | |
| 2023-06-20 | 2023-06-15 | MDGL | BATE KENNETH | Dir | A - Grant | $0.00 | +1,198 | 1,198 | New | $0 | |
| 2023-06-20 | 2023-06-15 | MDGL | Daly James M | Dir | A - Grant | $0.00 | +1,198 | 1,198 | New | $0 | |
| DM | 2023-03-02 | 2023-02-28+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | M - OptEx | $87.92 | +10.0K | 10.7K | +1,499% | +$879.2K |
| DM | 2023-03-02 | 2023-02-28+ | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | S - Sale+OE | $273.24 | -10.0K | 9,767 | -51% | -$2.73M |
| DM | 2023-01-19 | 2023-01-17 | MDGL | Levy Richard S | Dir | M - OptEx | $103.02 | +22.5K | 21.6K | New | +$2.32M |
| DM | 2023-01-19 | 2023-01-17 | MDGL | Levy Richard S | Dir | S - Sale+OE | $293.15 | -22.5K | 31.5K | -42% | -$6.59M |
| 2023-01-18 | 2023-01-16 | MDGL | Sukhija Remy | Chief Commercial Off | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 | |
| 2023-01-18 | 2023-01-16 | MDGL | Lynch Brian Joseph | SVP, GC | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 | |
| 2023-01-18 | 2023-01-16 | MDGL | Waltermire Robert E. | Senior VP, Chief Pharma Dev | A - Grant | $0.00 | +5,667 | 5,667 | New | $0 | |
| 2023-01-18 | 2023-01-16 | MDGL | Howarth Alex G. | CFO | A - Grant | $0.00 | +15.0K | 15.0K | New | $0 | |
| 2023-01-18 | 2023-01-16 | MDGL | FRIEDMAN PAUL A | CEO, Dir | A - Grant | $0.00 | +26.7K | 26.7K | New | $0 | |
| 2023-01-18 | 2023-01-16 | MDGL | Taub Rebecca | Pres, CMO, R, D, Dir | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 | |
| DM | 2023-01-06 | 2023-01-03 | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $282.92 | -13.0K | 100 | -99% | -$3.68M |
| D | 2023-01-06 | 2023-01-03 | MDGL | Lynch Brian Joseph | SVP, GC | M - OptEx | $91.79 | +13.0K | 13.0K | New | +$1.19M |
| DM | 2022-12-28 | 2022-12-23 | MDGL | Lynch Brian Joseph | SVP, GC | S - Sale+OE | $274.18 | -7,000 | 6,500 | -52% | -$1.92M |
| D | 2022-12-28 | 2022-12-23 | MDGL | Lynch Brian Joseph | SVP, GC | M - OptEx | $91.79 | +7,000 | 7,000 | New | +$642.5K |
Purchase Sale Sale after option exercise All abbreviations